Free Trial

Ardelyx (ARDX) News Today

Ardelyx logo
$5.04 -0.15 (-2.89%)
Closing price 04:00 PM Eastern
Extended Trading
$5.05 +0.01 (+0.20%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Trading Down 3.5% - Time to Sell?
Ardelyx (NASDAQ:ARDX) Stock Price Down 3.5% - What's Next?
Ardelyx, Inc. stock logo
Ardelyx, Inc. (NASDAQ:ARDX) Stock Position Lifted by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. lifted its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,035,135 shares of the biopharmaceutical company's stock aft
Ardelyx, Inc. stock logo
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Buy" from Brokerages
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) has been assigned an average rating of "Buy" from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommenda
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Shares Down 2.9% - Should You Sell?
Ardelyx (NASDAQ:ARDX) Stock Price Down 2.9% - What's Next?
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Upgraded by Piper Sandler to "Hold" Rating
Piper Sandler raised Ardelyx to a "hold" rating in a report on Wednesday.
Piper Sandler Sticks to Their Hold Rating for Ardelyx (ARDX)
Ardelyx, Inc. stock logo
Michael Raab Sells 41,668 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,668 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.36, for a total transaction of $223,340.48. Following the sale, the chief executive officer now owns 1,635,138 shares in the company, valued at $8,764,339.68. The trade was a 2.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Coverage Initiated at Scotiabank
Scotiabank began coverage on Ardelyx in a report on Friday. They set a "sector outperform" rating and a $15.00 price target for the company.
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Earns "Buy" Rating from LADENBURG THALM/SH SH
LADENBURG THALM/SH SH reaffirmed a "buy" rating and set a $11.00 price target on shares of Ardelyx in a research report on Friday.
Ardelyx initiated with an Outperform at Scotiabank
Ardelyx price target lowered to $11 from $13.50 at Ladenburg
Ardelyx, Inc. stock logo
Cantor Fitzgerald Comments on Ardelyx FY2025 Earnings
Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Ardelyx in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company will post earnings per share of (
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Rating Increased to Strong-Buy at Cantor Fitzgerald
Cantor Fitzgerald upgraded Ardelyx to a "strong-buy" rating in a research note on Tuesday.
Ardelyx initiated with a Buy at BTIG
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Now Covered by Analysts at BTIG Research
BTIG Research began coverage on shares of Ardelyx in a research report on Tuesday. They set a "buy" rating and a $14.00 price objective on the stock.
Ardelyx, Inc. stock logo
Jones Financial Companies Lllp Grows Stake in Ardelyx, Inc. (NASDAQ:ARDX)
Jones Financial Companies Lllp increased its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 67.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,452,176 shares of the biopharmaceutic
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Stock Price Up 5.3% on Insider Buying Activity
Ardelyx (NASDAQ:ARDX) Trading Up 5.3% on Insider Buying Activity
Ardelyx, Inc. stock logo
Los Angeles Capital Management LLC Purchases 299,275 Shares of Ardelyx, Inc. (NASDAQ:ARDX)
Los Angeles Capital Management LLC grew its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 175.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 469,819 shares of the biopharmaceutical compan
Ardelyx, Inc. stock logo
Ardelyx, Inc. (NASDAQ:ARDX) Director Acquires $388,645.00 in Stock
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) Director David M. Mott acquired 77,729 shares of Ardelyx stock in a transaction dated Monday, February 24th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $388,645.00. Following the completion of the acquisition, the director now directly owns 2,015,494 shares in the company, valued at approximately $10,077,470. This represents a 4.01 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Ardelyx announces approval of NDA by China for tenapanor
Tenapanor Approved in China for Hyperphosphatemia
Ardelyx to Participate in Upcoming Investor Conferences
Ardelyx, Inc. stock logo
Ardelyx, Inc. (NASDAQ:ARDX) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, five have issued
Ardelyx, Inc. stock logo
FY2029 Earnings Estimate for Ardelyx Issued By HC Wainwright
Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - HC Wainwright issued their FY2029 EPS estimates for Ardelyx in a research note issued to investors on Friday, February 21st. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will post earnings per share of $1.18 for the year. H
Ardelyx, Inc. stock logo
FY2029 Earnings Estimate for Ardelyx Issued By Wedbush
Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Wedbush reduced their FY2029 EPS estimates for Ardelyx in a note issued to investors on Friday, February 21st. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of $0.88 per share for the year, down from thei
Ardelyx, Inc. stock logo
Q3 Earnings Estimate for Ardelyx Issued By Leerink Partnrs
Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Ardelyx in a research note issued to investors on Thursday, February 20th. Leerink Partnrs analyst R. Ruiz expects that the biopharmaceutical company will post earnings o
Ardelyx, Inc. stock logo
Ardelyx, Inc. (NASDAQ:ARDX) Insider Laura A. Williams Sells 4,941 Shares
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura A. Williams sold 4,941 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total value of $27,768.42. Following the sale, the insider now directly owns 303,804 shares in the company, valued at $1,707,378.48. This represents a 1.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Ardelyx, Inc. stock logo
Justin A. Renz Sells 5,171 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CFO Justin A. Renz sold 5,171 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total value of $29,061.02. Following the transaction, the chief financial officer now directly owns 285,968 shares in the company, valued at $1,607,140.16. The trade was a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Ardelyx, Inc. stock logo
Michael Raab Sells 22,964 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 22,964 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $5.62, for a total transaction of $129,057.68. Following the completion of the transaction, the chief executive officer now directly owns 1,085,755 shares of the company's stock, valued at approximately $6,101,943.10. The trade was a 2.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Shares Down 7.6% - What's Next?
Ardelyx (NASDAQ:ARDX) Shares Down 7.6% - What's Next?
Ardelyx, Inc. stock logo
Raymond James Reaffirms Strong-Buy Rating for Ardelyx (NASDAQ:ARDX)
Raymond James reiterated a "strong-buy" rating and set a $13.00 price target (down previously from $15.00) on shares of Ardelyx in a research note on Friday.
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Receives "Neutral" Rating from HC Wainwright
HC Wainwright reissued a "neutral" rating and issued a $5.50 price objective on shares of Ardelyx in a research note on Friday.
Ardelyx, Inc. stock logo
Hussman Strategic Advisors Inc. Sells 147,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX)
Hussman Strategic Advisors Inc. lowered its position in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 41.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 210,000 shares of the biopharmace
Ardelyx price target lowered to $13 from $15 at Raymond James
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Shares Gap Down - Should You Sell?
Ardelyx (NASDAQ:ARDX) Shares Gap Down - Time to Sell?
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Issues Earnings Results
Ardelyx (NASDAQ:ARDX - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. Ardelyx had a negative net margin of 28.82% and a negative return on equity of 46.60%.
Ardelyx, Inc. stock logo
Ardelyx (NASDAQ:ARDX) Releases Earnings Results, Hits Estimates
Ardelyx (NASDAQ:ARDX - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.02. Ardelyx had a negative return on equity of 46.60% and a negative net margin of 28.82%.
Remove Ads
Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

ARDX Media Mentions By Week

ARDX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARDX
News Sentiment

0.71

0.89

Average
Medical
News Sentiment

ARDX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARDX Articles
This Week

5

9

ARDX Articles
Average Week

Remove Ads
Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ARDX) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners